ストックスクリーナーアプリを入手
2.98
51.70%
-3.19
アフターアワーズ：
2.99
0.01
+0.34%
前日終値:
$6.17
開ける：
$4.47
24時間の取引高:
12.45M
Relative Volume:
11.15
時価総額：
$236.22M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-36.52
EPS:
-0.0816
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
-66.59%
1か月 パフォーマンス:
-76.54%
6か月 パフォーマンス:
-81.26%
1年 パフォーマンス:
+15.41%
1日の値動き範囲:
$2.94
$4.59
1週間の範囲:
$2.94
$8.93
52週間の値動き範囲:
$2.28
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CATX | 2.98 | 236.22M | 6.96M | -46.51M | -37.99M | -0.0816 |
| ABT | 117.25 | 201.08B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 390.05 | 147.64B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 91.51 | 134.72B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 84.71 | 107.85B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 70.38 | 41.30B | 6.60B | 4.16B | 490.10M | 2.34 |
Perspective Therapeutics Inc (CATX) 最新ニュース
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - The Manila Times
Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings - MarketBeat
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 - The Manila Times
Avidity Partners Management LP Bolsters Portfolio with Perspecti - GuruFocus.com
Analysis of COMMODORE CAPITAL LP's Recent Transaction in Perspec - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson Group PLC Increases Stake in Perspective Therape - GuruFocus.com
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus By Investing.com - Investing.com South Africa
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's potential in focus - Investing.com
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Perspective Therapeutics Reports Strong Cash Position and Clinical Advances - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results - The Manila Times
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
WealthPlan Investment Management LLC Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics Reports $267.8M Cash Position, Advances Cancer Drug Trials | CATX Stock News - StockTitan
FMR LLC Acquires Shares in Perspective Therapeutics Inc - GuruFocus.com
Lantheus Reports Third Quarter 2024 Financial Results - The Manila Times
Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.63 Consensus Price Target from Analysts - MarketBeat
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Perspective Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq
Perspective Therapeutics targeting tumors - The Gazette
Hills Bank & Trust Co Takes $13.72 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results - The Manila Times
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November - The Manila Times
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's lead-212 edge - Investing.com India
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
1,602,283 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Nicholson Wealth Management Group LLC - MarketBeat
Perspective Therapeutics (NYSE:CATX) Shares Gap UpStill a Buy? - MarketBeat
Perspective Therapeutics initiated with a Buy at UBS - TipRanks
Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush - MarketBeat
Market undervaluing Perspective Therapeutics stock amid upcoming trial data, says UBS - Investing.com
Perspective Therapeutics (NYSE:CATX) Now Covered by UBS Group - MarketBeat
Perspective Therapeutics presents updates at 37th Annual Congress of EANM - TipRanks
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine - The Manila Times
Immunodeficiency Therapeutics Market Analysis by Industry - openPR
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Oppenheimer maintains outperform rating on CATX shares amid new data - Investing.com India
Siemens Healthineers Gets FDA Clearance for Alzheimer’s Disease Analysis Features - Imaging Technology News
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Perspective Therapeutics Inc (CATX) Shares Up 4.38% on Oct 16 - GuruFocus.com
Perspective begins shipping investigational products from facility in NJ - TipRanks
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - The Manila Times
Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - Marketscreener.com
Perspective Therapeutics (NYSE:CATX) Trading Up 4.9%Should You Buy? - MarketBeat
Perspective Therapeutics Inc (CATX) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.80%
大文字化:
|
ボリューム (24 時間):